Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Department of Obstetrics and Gynecology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Eur J Endocrinol. 2021 May;184(5):R177-R192. doi: 10.1530/EJE-20-1178.
Fertility and ovarian protection against chemotherapy-associated ovarian damage has formed a new field called oncofertility, which is driven by the pursuit of fertility protection as well as good life quality for numerous female cancer survivors. However, the choice of fertility and ovarian protection method is a difficult problem during chemotherapy and there is no uniform guideline at present. To alleviate ovarian toxicity caused by anticancer drugs, effective methods combined with an individualized treatment plan that integrates an optimal strategy for preserving and restoring reproductive function should be offered from well-established to experimental stages before, during, and after chemotherapy. Although embryo, oocyte, and ovarian tissue cryopreservation are the major methods that have been proven effective and feasible for fertility protection, they are also subject to many limitations. Therefore, this paper mainly discusses the future potential methods and corresponding mechanisms for fertility protection in chemotherapy-associated ovarian damage.
生育力保护和对抗化疗相关卵巢损伤的策略形成了一个新的领域，称为肿瘤生育力保护，这是由保护生育力以及为数众多的女性癌症幸存者的生活质量所推动的。然而，在化疗过程中，生育力和卵巢保护方法的选择是一个难题，目前尚无统一的指南。为了减轻抗癌药物引起的卵巢毒性，应在化疗前、化疗期间和化疗后从已建立的到实验阶段提供结合保留和恢复生殖功能的最佳策略的个体化治疗方案的有效方法。虽然胚胎、卵母细胞和卵巢组织冷冻保存是已被证明对生育力保护有效的且可行的主要方法，但它们也受到许多限制。因此，本文主要讨论了化疗相关卵巢损伤中生育力保护的未来潜在方法及其相应机制。
